| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥5.8B | ¥6.4B | -9.0% |
| Operating Income | ¥-20.7B | ¥-20.8B | +0.1% |
| Ordinary Income | ¥-21.4B | ¥-20.8B | -3.1% |
| Net Income | ¥-21.4B | ¥-21.7B | +1.2% |
| ROE | -693.2% | -87.6% | - |
FY2025 consolidated results show revenue of 5.8B yen (YoY -9.0%), operating loss of 20.7B yen (YoY +0.1% improvement), ordinary loss of 21.4B yen (YoY -3.1%), and net loss of 21.4B yen (YoY +1.2% improvement). Despite high gross profit margin of 67.0%, the company continues to record substantial operating losses driven by selling, general and administrative expenses of 24.6B yen, which far exceed total revenue. Cash and deposits declined sharply from 21.1B yen to 5.2B yen (YoY -75.5%), raising near-term liquidity concerns. Total assets decreased to 12.3B yen from 27.7B yen, while total equity contracted to 3.1B yen from 24.8B yen, resulting in a debt-to-equity ratio of approximately 2.98. Operating cash flow was negative 21.6B yen, closely aligned with net loss, indicating cash consumption consistent with earnings performance. The company maintains a no-dividend policy given the loss-making status.
Revenue declined 9.0% YoY to 5.8B yen, with the Drug Discovery Support segment generating 579M yen in sales (down from 636M yen prior year), representing a 9.0% contraction in the company's sole revenue-generating segment. The Drug Discovery segment generated no external revenue. Despite the revenue decline, gross profit margin remained robust at 67.0%, indicating strong pricing power and favorable cost structure at the product level. However, operating loss remained substantial at 20.7B yen, essentially flat from the prior year's 20.8B yen loss. The persistent operating deficit is attributable to SG&A expenses of 24.6B yen, which represent 425% of revenue, reflecting the company's stage as a development-stage biopharmaceutical enterprise with significant fixed costs in research personnel, facilities, and infrastructure. The gap between ordinary loss (21.4B yen) and operating loss (20.7B yen) is approximately 700M yen, representing non-operating expenses that include interest expense on debt and convertible instruments. Net loss of 21.4B yen improved marginally from 21.7B yen prior year, driven by slightly lower extraordinary losses. Impairment loss of 25M yen was recorded during the period as a non-recurring factor. The performance pattern is characterized as revenue down/loss essentially flat, indicating structural profitability challenges requiring either substantial revenue expansion or cost restructuring to achieve breakeven.
The Drug Discovery Support segment recorded revenue of 579M yen with an operating loss of 51M yen, representing the company's commercial business providing kinase proteins, assay development, and profiling services to external customers. This segment constitutes the company's sole revenue source and is the core commercial operation. The Drug Discovery segment, representing internal drug development activities, recorded operating loss of 2,024M yen with no external revenue, accounting for 97.6% of total consolidated operating losses. This segment reflects the company's investment in proprietary kinase inhibitor research and development programs. The margin differential is significant: Drug Discovery Support operates near breakeven at segment level with an operating margin of -8.8%, while Drug Discovery operates with no revenue base and represents pure investment expenditure. The segment results highlight the company's dual business model challenges - sustaining commercial service revenue growth while funding capital-intensive internal drug discovery programs.
[Profitability] Operating margin was -358.2% (deteriorated from -326.5% prior year due to revenue contraction), with gross profit margin of 67.0% remaining strong. ROE was -702.6%, driven by substantial net losses against a reduced equity base of 3.1B yen. Return on assets was -176.5%, reflecting operating losses against total assets of 12.3B yen. [Cash Quality] Cash and equivalents declined to 5.2B yen from 21.1B yen prior year, representing coverage of 3.1x for short-term debt of 1.7B yen. Operating cash flow to net income ratio was 0.99, indicating earnings performance aligned with cash generation. [Investment Efficiency] Asset turnover ratio was 0.47, reflecting low revenue generation relative to asset base. Inventory turnover days increased substantially to 295 days (vs 171 days prior year), indicating significant inventory accumulation. Days sales outstanding increased to 238 days (vs 160 days prior year), suggesting collection challenges or contract structure changes. [Financial Health] Equity ratio declined to 25.1% from 89.5% prior year, reflecting substantial equity erosion from accumulated losses and potential capital restructuring. Current ratio remained elevated at 699.4% (current assets of 11.8B yen vs current liabilities of 1.7B yen). Debt-to-equity ratio was 2.98, representing high leverage for a development-stage enterprise. Fixed liabilities of 7.5B yen represent 82% of total liabilities, with convertible bonds recorded at 681M yen indicating potential future dilution.
Operating cash flow was negative 21.6B yen, representing 0.99x of net loss and confirming cash-backed operating losses. The substantial cash outflow reflects ongoing research and development expenditures in the Drug Discovery segment and operating expenses exceeding revenue in commercial operations. Investing cash flow was negative 250M yen, primarily consisting of capital expenditures of 90M yen for equipment and intangible assets, representing 0.30x of depreciation expense of 310M yen and indicating investment restraint. Financing cash flow was positive 6.0B yen, driven by debt or equity issuance activities to fund operations, though specific sources are not detailed. Free cash flow was negative 21.8B yen, confirming that operations consume cash substantially exceeding investment needs. Cash and deposits declined 15.9B yen from 21.1B yen to 5.2B yen despite the financing inflow, as operating cash burn exceeded capital raised. The cash position at period end represents approximately 2.9 months of operating cash flow at current burn rate, indicating heightened near-term liquidity risk requiring additional capital infusion or operational improvement to sustain business continuity.
Ordinary loss of 21.4B yen versus operating loss of 20.7B yen shows non-operating net expense of approximately 700M yen, consisting primarily of interest expense on debt obligations and convertible instruments. Non-operating expenses represent 12.1% of revenue, comprising interest expenses that are recurring in nature given the debt structure. Financial income and equity method gains were minimal or absent, indicating limited contribution from non-core activities. The gap between operating and ordinary income is structural and driven by financing costs rather than one-time factors. Operating cash flow of negative 21.6B yen closely tracks net loss of 21.4B yen with a ratio of 0.99, indicating high earnings quality in terms of cash backing despite the loss position. Working capital deterioration was evident with inventory turnover days increasing to 295 days from 171 days and DSO increasing to 238 days from 160 days, suggesting potential accrual management concerns or operational inefficiencies in collections and inventory management. The consistency between cash losses and accounting losses supports earnings quality, though the magnitude of ongoing losses raises questions about business model sustainability.
The company forecasts full-year revenue of 7.2B yen, operating loss of 20.3B yen, ordinary loss of 20.5B yen, and net loss of 20.9B yen. Given that current full-year results show revenue of 5.8B yen and operating loss of 20.7B yen, the revenue forecast implies expectation of partial-year visibility or represents an annual run-rate target not yet achieved. The forecast implies revenue growth of 24.4% compared to current year actual results. Operating loss guidance of 20.3B yen represents only marginal improvement from current 20.7B yen, suggesting limited near-term path to profitability despite anticipated revenue growth. The guidance indicates management expects revenue momentum to resume but does not project breakthrough improvement in loss profile, implying continued substantial cash consumption and funding requirements. The modest loss reduction despite 24% revenue growth forecast suggests limited operating leverage, with incremental revenues absorbed by ongoing fixed cost base or continued R&D investment in the Drug Discovery segment.
Annual dividend is zero yen with no change from prior year. The company maintains a no-dividend policy given the loss-making financial position. Payout ratio is not applicable given zero dividend and negative earnings. No share buyback activity was disclosed during the period. Total return ratio is zero as no cash returns were provided to shareholders. The absence of shareholder distributions is consistent with the company's development stage, negative free cash flow of 21.8B yen, and need to preserve cash for operations and debt service. Reinstatement of dividends would require achievement of sustainable profitability and positive free cash flow generation, which current guidance does not project for the near term.
Severe liquidity deterioration represents the most immediate risk, with cash declining 75.5% to 5.2B yen while operating cash flow burn rate remains at approximately 21.6B yen annually, providing only 2.9 months of runway at current consumption levels. The company requires successful external financing or rapid operational turnaround to sustain operations beyond the near term. High financial leverage with debt-to-equity ratio of 2.98 constrains financial flexibility and increases refinancing risk. Fixed liabilities of 7.5B yen include convertible debt of 681M yen that may require refinancing or result in dilutive equity conversion if business performance does not improve. Revenue concentration and customer dependency in the Drug Discovery Support segment creates business sustainability risk, particularly as this segment contracted 9.0% while representing 100% of external revenue. Failure to retain key customers or expand the customer base would further pressure liquidity and operational viability.
[Industry Position] (Reference - Proprietary Analysis) The company operates in the biopharmaceutical research services and drug discovery sector. Operating margin of -358.2% is substantially below industry norms for commercial-stage pharmaceutical service providers, reflecting the company's hybrid model of commercial services alongside capital-intensive internal drug development. Development-stage biotechnology companies typically operate with negative margins during research phases, though the magnitude of losses relative to revenue base is notable. Equity ratio of 25.1% is low compared to typical industry standards where 40-60% equity ratios provide financial stability, indicating significant capital structure stress. The revenue contraction of 9.0% YoY contrasts with general industry expansion trends in contract research and drug discovery services, suggesting company-specific competitive or operational challenges. The high SG&A ratio of 425% of sales far exceeds sustainable levels for commercial operations and reflects structural cost-revenue misalignment. ROE comparison is not meaningful given negative earnings. The company's financial profile suggests heightened distress risk relative to peer commercial-stage research services firms, while capital consumption patterns are consistent with early-stage drug developers lacking commercial product revenues.
The financial results reveal a company at a critical inflection point, with substantial cash burn of 21.6B yen annually against rapidly diminishing cash reserves of 5.2B yen, indicating approximately 2.9 months of liquidity runway at current consumption rates. This creates near-term capital raising imperative or operational restructuring necessity. The business model demonstrates bifurcation between a marginally loss-making commercial service business (Drug Discovery Support with -9% revenue growth and -51M yen operating loss) and a heavily cash-consumptive internal development program (Drug Discovery with -2,024M yen operating loss). The 75% decline in cash position despite 6.0B yen in financing cash flow during the period indicates that external capital raised was insufficient to offset operational burn, suggesting either inadequate capital raising or acceleration of cash consumption. High gross margins of 67% in the commercial business indicate potential profitability if SG&A expense structure can be rationalized or revenue scale expanded significantly. However, current guidance projecting only marginal loss improvement despite 24% revenue growth forecast suggests limited operating leverage or continued heavy investment, implying multi-year path to profitability. The deterioration in working capital metrics, particularly inventory days increasing to 295 and DSO increasing to 238 days, signals operational stress in contract execution, customer collections, or potential recognition practices requiring monitoring.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.